Moderna announces interim phase 3 safety and immunogenicity results for mrna-1010, a seasonal influenza vaccine candidate

Mrna-1010 demonstrated superiority on seroconversion rates for a/h3n2 and a/h1n1, superiority on geometric mean titer ratios for a/h3n2, and non-inferiority on geometric mean titer ratios for a/h1n1 non-inferiority was not met for seroconversion rates and geometric mean titer ratios for the influenza b/victoria- and b/yamagata-lineage strains mrna-1010 showed an acceptable safety and tolerability profile separate parallel pivotal phase 3 efficacy study has now accrued over 200 pcr-confirmed cases, almost all influenza a consistent with the burden of disease in older adults; an independent dsmb is expected to review the first interim analysis of efficacy by the end of 1q mrna-1010 is one of five influenza vaccine candidates being evaluated by moderna cambridge, ma / accesswire / february 16, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced interim results from its pivotal phase 3 safety and immunogenicity trial of mrna-1010 (p301), an mrna-based seasonal influenza (flu) vaccine candidate, in adults. the phase 3 randomized trial was designed to evaluate the safety and immunogenicity of mrna-1010 in adults 18 years and older in the southern hemisphere.
MRNA Ratings Summary
MRNA Quant Ranking